Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Lenalidomide may stimulate the immune system in different ways and
stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Sorafenib and lenalidomide may also stop the growth of cancer cells by
blocking blood flow to the cancer. Giving sorafenib together with lenalidomide and
dexamethasone may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of sorafenib when
given together with lenalidomide and dexamethasone and to see how well they work in treating
patients with relapsed or refractory multiple myeloma.